Source comparison
Follistatin-344 vs MK-677: Research Compound Comparison
Understanding the distinctions between follistatin-344 vs MK-677 requires side-by-side evaluation across mechanism, application, administration, and research suitability. Primary Mechanism Myostatin and activin inhibitor. Binds TGF-beta superfamily proteins to
This comparison does not assign a generated winner or score.
- Understanding the distinctions between follistatin-344 vs MK-677 requires side-by-side evaluation across mechanism, application, administration, and research suitability.
- Primary Mechanism
- Myostatin and activin inhibitor. Binds TGF-beta superfamily proteins to prevent receptor activation and downstream SMAD signaling
- Ghrelin receptor agonist (GHSR-1a). Stimulates pituitary growth hormone release and hepatic IGF-1 production
- Follistatin operates locally at muscle tissue; MK-677 operates systemically through endocrine axis
- Half-Life
- 3–4 hours. Requires twice-daily dosing to maintain therapeutic plasma concentrations
- 24 hours. Once-daily administration sufficient for consistent receptor occupancy
- MK-677's extended half-life simplifies research protocols significantly
- Administration Route
- Subcutaneous or intramuscular injection after reconstitution with bacteriostatic water
- Oral administration (capsule or powder suspension). No injection required
- MK-677 eliminates injection-related variables and improves protocol compliance
- Storage Requirements
- Unreconstituted: −20°C. Reconstituted: 2–8°C, use within 14–21 days. Temperature-sensitive glycoprotein
- Powder: room temperature stable. Capsules: 12–24 months at room temperature. No refrigeration required
- Follistatin-344 requires cold chain infrastructure; MK-677 does not
- Research Applications
- Myostatin inhibition studies, muscular dystrophy models, sarcopenia research, muscle regeneration after injury
- Growth hormone deficiency models, aging research, body composition studies, bone density investigations, sleep quality protocols
- Select based on whether myostatin pathway or GH/IGF-1 axis is the experimental variable
- Typical Research Dosing
- 100–300mcg per injection, twice daily for protocols maintaining plasma levels
- 10–25mg once daily, typically evening administration to align with endogenous GH pulsatility
- Follistatin requires more frequent dosing due to short half-life